Gert Fricker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9045826/publications.pdf

Version: 2024-02-01

		36303	53230
171	8,670 citations	51	85
papers	citations	h-index	g-index
181	181	181	9700
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Engaging neuroscience to advance translational research in brain barrier biology. Nature Reviews Neuroscience, 2011, 12, 169-182.	10.2	508
2	Xenobiotic Transport across Isolated Brain Microvessels Studied by Confocal Microscopy. Molecular Pharmacology, 2000, 58, 1357-1367.	2.3	291
3	Phospholipids and Lipid-Based Formulations in Oral Drug Delivery. Pharmaceutical Research, 2010, 27, 1469-1486.	3.5	289
4	Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation, 2002, 110, 1309-1318.	8.2	280
5	Rapid Modulation of P-Glycoprotein-Mediated Transport at the Blood-Brain Barrier by Tumor Necrosis Factor-α and Lipopolysaccharide. Molecular Pharmacology, 2006, 69, 462-470.	2.3	185
6	Interactions of HIV Protease Inhibitors with ATP-Dependent Drug Export Proteins. Molecular Pharmacology, 1999, 56, 383-389.	2.3	178
7	HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochemical Pharmacology, 1999, 57, 1147-1152.	4.4	176
8	Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation, 2002, 110, 1309-1318.	8.2	159
9	Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations― European Journal of Pharmaceutical Sciences, 2013, 50, 8-16.	4.0	158
10	Rapid Regulation of P-Glycoprotein at the Blood-Brain Barrier by Endothelin-1. Molecular Pharmacology, 2004, 66, 387-394.	2.3	152
11	Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. Journal of Neurochemistry, 2006, 97, 899-910.	3.9	147
12	Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment. Colloids and Surfaces B: Biointerfaces, 2016, 145, 8-13.	5.0	140
13	Closing the Gaps: A Full Scan of the Intestinal Expression of P-Glycoprotein, Breast Cancer Resistance Protein, and Multidrug Resistance-Associated Protein 2 in Male and Female Rats. Drug Metabolism and Disposition, 2008, 36, 1249-1254.	3.3	137
14	Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the <i>p</i> -Glycoprotein (ABCB1) Modulator Tariquidar. Journal of Medicinal Chemistry, 2009, 52, 1190-1197.	6.4	135
15	Modulation of p-Glycoprotein Transport Function at the Blood-Brain Barrier. Experimental Biology and Medicine, 2005, 230, 118-127.	2.4	130
16	Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: True supersaturation vs. apparent solubility enhancement. International Journal of Pharmaceutics, 2012, 437, 288-293.	5.2	129
17	Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 1-9.	4.3	124
18	ABC transporters at the blood–brain barrier. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 499-508.	3.3	121

#	Article	IF	Citations
19	By-passing of P-glycoprotein Using Immunoliposomes. Journal of Drug Targeting, 2002, 10, 73-79.	4.4	120
20	In vitro models to evaluate the permeability of poorly soluble drug entities: Challenges and perspectives. European Journal of Pharmaceutical Sciences, 2012, 45, 235-250.	4.0	113
21	Evidence for Pâ€glycoproteinâ€modulated penetration of morphineâ€6â€glucuronide into brain capillary endothelium. British Journal of Pharmacology, 1996, 118, 1879-1885.	5.4	108
22	Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharmaceutical Research, 1999, 16, 402-407.	3 . 5	105
23	Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies. International Journal of Pharmaceutics, 2012, 439, 49-62.	5.2	104
24	Endocytosis and Transcytosis of an Immunoliposome-Based Brain Drug Delivery System. Journal of Drug Targeting, 2000, 8, 435-446.	4.4	101
25	Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome®) of Boswellia extract. Fìtoterapìâ, 2013, 84, 89-98.	2.2	101
26	Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. European Journal of Pharmaceutical Sciences, 2010, 40, 25-32.	4.0	96
27	Modulation of Drug Transporters at the Blood-Brain Barrier. Pharmacology, 2004, 70, 169-176.	2.2	93
28	What Is the Mechanism Behind Increased Permeation Rate of a Poorly Soluble Drug from Aqueous Dispersions of an Amorphous Solid Dispersion?. Journal of Pharmaceutical Sciences, 2014, 103, 1779-1786.	3.3	91
29	Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. British Journal of Pharmacology, 2003, 140, 1201-1210.	5.4	86
30	Pregnane X Receptor (PXR) Regulates P-Glycoprotein at the Blood-Brain Barrier: Functional Similarities between Pig and Human PXR. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 141-149.	2.5	80
31	Delivery of nanoparticles to the brain detected by fluorescence microscopy. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 627-632.	4.3	77
32	The ABC of the Blood-Brain Barrier - Regulation of Drug Efflux Pumps. Current Pharmaceutical Design, 2011, 17, 2762-2770.	1.9	72
33	Cloning and Characterization of a Novel Apolipoprotein A-I Binding Protein, AI-BP, Secreted by Cells of the Kidney Proximal Tubules in Response to HDL or ApoA-I. Genomics, 2002, 79, 693-702.	2.9	69
34	Xenobiotic efflux pumps in isolated fish brain capillaries. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2002, 282, R191-R198.	1.8	69
35	Oral delivery of vancomycin by tetraether lipid liposomes. European Journal of Pharmaceutical Sciences, 2017, 108, 111-118.	4.0	69
36	In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 359-365.	2.8	67

#	Article	IF	CITATIONS
37	Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 416-422.	4.3	67
38	Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastro-intestinal fluids. International Journal of Pharmaceutics, 2011, 405, 210-217.	5.2	67
39	SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity. Life Sciences, 1993, 53, 517-525.	4.3	66
40	Glutaric aciduria type I and methylmalonic aciduria: Simulation of cerebral import and export of accumulating neurotoxic dicarboxylic acids in in vitro models of the blood–brain barrier and the choroid plexus. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 552-560.	3.8	64
41	Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound. European Journal of Pharmaceutical Sciences, 2012, 47, 16-20.	4.0	61
42	Improved Oral Bioavailability of Human Growth Hormone by a Combination of Liposomes Containing Bio-Enhancers and Tetraether Lipids and Omeprazole. Journal of Pharmaceutical Sciences, 2014, 103, 3985-3993.	3.3	61
43	Characterization of Cytochrome P450 Protein Expression along the Entire Length of the Intestine of Male and Female Rats. Drug Metabolism and Disposition, 2008, 36, 1039-1045.	3.3	60
44	Oral peptide delivery by tetraether lipid liposomes. International Journal of Pharmaceutics, 2011, 415, 150-157.	5.2	60
45	In vitro metabolism, permeation, and brain availability of six major boswellic acids from Boswellia serrata gum resins. Fìtoterapìâ, 2013, 84, 99-106.	2.2	60
46	Relevance of Multidrug Resistance Proteins for Intestinal Drug Absorptionin vitroandin vivo. Basic and Clinical Pharmacology and Toxicology, 2002, 90, 5-13.	0.0	58
47	Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood–brain barrier, in human whole blood and in vivo. Journal of Controlled Release, 2015, 197, 165-179.	9.9	58
48	In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants. Journal of Pharmacy and Pharmacology, 2011, 63, 1022-1030.	2.4	56
49	Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2. European Journal of Pharmaceutical Sciences, 2009, 36, 275-284.	4.0	55
50	Surveillance of siRNA integrity by FRET imaging. Nucleic Acids Research, 2007, 35, e124.	14.5	54
51	Cytotoxicity and P-Glycoprotein Modulating Effects of Quinolones and Indoloquinazolines from the Chinese Herb <i>Evodia rutaecarpa</i>). Planta Medica, 2007, 73, 1554-1557.	1.3	53
52	Dual ligand immunoliposomes for drug delivery to the brain. Colloids and Surfaces B: Biointerfaces, 2015, 134, 213-219.	5.0	52
53	Enteral absorption of octreotide: absorption enhancement by polyoxyethyleneâ€24â€cholesterol ether. British Journal of Pharmacology, 1993, 108, 298-303.	5.4	51
54	Cyclodextrins $\hat{a} \in \text{``Useful excipients for oral peptide administration?. International Journal of Pharmaceutics, 1996, 137, 103-110.}$	5.2	50

#	Article	IF	Citations
55	Choroid plexus epithelial monolayers-a cell culture model from porcine brain. Cerebrospinal Fluid Research, 2006, 3, 13.	0.5	50
56	Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties. Journal of Cellular and Molecular Medicine, 2011, 15, 1122-1135.	3.6	49
57	Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine. European Journal of Pharmaceutical Sciences, 2000, 10, 133-140.	4.0	48
58	Enhancement of Oral Bioavailability of E804 by Self-Nanoemulsifying Drug Delivery System (SNEDDS) in Rats. Journal of Pharmaceutical Sciences, 2013, 102, 3792-3799.	3.3	47
59	Short- and Long-Term Influences of Heavy Metals on Anionic Drug Efflux from Renal Proximal Tubule. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 578-585.	2.5	45
60	Permeability of porcine blood brain barrier to somatostatin analogues. British Journal of Pharmacology, 2002, 135, 1308-1314.	5.4	45
61	Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharmaceutical Research, 2003, 20, 1170-1176.	3.5	45
62	Development of a New Method to Assess Nanocrystal Dissolution Based on Light Scattering. Pharmaceutical Research, 2012, 29, 2887-2901.	3.5	45
63	Establishment of Optimized MDCK Cell Lines for Reliable Efflux Transport Studies. Journal of Pharmaceutical Sciences, 2014, 103, 1298-1304.	3.3	44
64	Intestinal absorption of the octapeptide SMS 201–995 visualized by fluorescence derivatization. Gastroenterology, 1991, 100, 1544-1552.	1.3	43
65	BCRP at the Bloodâ^Brain Barrier: Genomic Regulation by 17β-Estradiol. Molecular Pharmaceutics, 2010, 7, 1835-1847.	4.6	43
66	Ivermectin excretion by isolated functionally intact brain endothelial capillaries. British Journal of Pharmacology, 2001, 132, 722-728.	5.4	42
67	In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier. Journal of Pharmacy and Pharmacology, 2010, 62, 1591-1598.	2.4	42
68	Current Concepts in Intestinal Peptide Absorption. Journal of Peptide Science, 1996, 2, 195-211.	1.4	41
69	Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries. Journal of Drug Targeting, 2009, 17, 610-618.	4.4	41
70	Blood Trimethylamine-N-Oxide Originates from Microbiota Mediated Breakdown of Phosphatidylcholine and Absorption from Small Intestine. PLoS ONE, 2017, 12, e0170742.	2.5	40
71	Sister of P-glycoprotein expression in different tissues. Biochemical Pharmacology, 1999, 57, 833-835.	4.4	39
72	St. John's Wort Constituents Modulate P-glycoprotein Transport Activity at the Blood-Brain Barrier. Pharmaceutical Research, 2010, 27, 811-822.	3.5	39

#	Article	IF	CITATIONS
73	Liposomal Conjugates for Drug Delivery to the Central Nervous System. Pharmaceutics, 2015, 7, 27-42.	4.5	39
74	Modulation of transendothelial permeability and expression of ATP-binding cassette transporters in cultured brain capillary endothelial cells by astrocytic factors and cell-culture conditions. Experimental Brain Research, 2003, 153, 356-365.	1.5	38
75	Dynamic Regulation of P-glycoprotein in Human Brain Capillaries. Molecular Pharmaceutics, 2013, 10, 3333-3341.	4.6	38
76	The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility. International Journal of Nanomedicine, 2012, 7, 5757.	6.7	37
77	Epithelial transport of anthelmintic ivermectin in a novel model of isolated proximal kidney tubules. Pharmaceutical Research, 1999, 16, 1570-1575.	3.5	36
78	Identification of [¹⁸ F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging. Journal of Medicinal Chemistry, 2018, 61, 1737-1743.	6.4	36
79	Nasal delivery of octreotide: Absorption enhancement by particulate carrier systems. International Journal of Pharmaceutics, 1996, 139, 25-32.	5.2	35
80	P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. British Journal of Pharmacology, 2000, 129, 251-256.	5.4	35
81	In vitro evaluation of liposomes containing bio-enhancers for the oral delivery of macromolecules. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 394-403.	4.3	35
82	Archaeal lipids in oral delivery of therapeutic peptides. European Journal of Pharmaceutical Sciences, 2017, 108, 101-110.	4.0	35
83	Modification with Organometallic Compounds Improves Crossing of the Blood–Brain Barrier of [Leu ⁵]â€Enkephalin Derivatives in an In Vitro Model System. ChemBioChem, 2009, 10, 1852-1860.	2.6	34
84	Formulation optimization of itraconazole loaded PEGylated liposomes for parenteral administration by using design of experiments. International Journal of Pharmaceutics, 2013, 448, 189-197.	5.2	34
85	Current Status in the Therapy of Liver Diseases. International Journal of Molecular Sciences, 2014, 15, 7500-7512.	4.1	34
86	Quantification and visualization of the transport of octreotide, a somatostatin analogue, across monolayers of cerebrovascular endothelial cells. Pharmaceutical Research, 1994, 11, 442-448.	3.5	33
87	Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine, 2014, 21, 323-332.	5.3	33
88	Delivery of Copper-chelating Trientine (TETA) to the central nervous system by surface modified liposomes. International Journal of Pharmaceutics, 2016, 512, 87-95.	5.2	33
89	Quantitation of Lysosomal Trapping of Basic Lipophilic Compounds Using In Vitro Assays and In Silico Predictions Based on the Determination of the Full pH Profile of the Endo-/Lysosomal System in Rat Hepatocytes. Drug Metabolism and Disposition, 2019, 47, 49-57.	3.3	33
90	Confocal imaging of organic anion transport in intact rat choroid plexus. American Journal of Physiology - Renal Physiology, 2002, 282, F877-F885.	2.7	32

#	Article	IF	CITATIONS
91	Compound profiling for ABCC2 (MRP2) using a fluorescent microplate assay system. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 396-403.	4.3	32
92	Identification of Different Transport Systems for Bile Salts in Sinusoidal and Canalicular Membranes of Hepatocytes. Biological Chemistry Hoppe-Seyler, 1987, 368, 1143-1150.	1.4	31
93	Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis. International Journal of Pharmaceutics, 2012, 437, 253-263.	5. 2	30
94	Effect of Phospholipid-Based Formulations of <i>Boswellia serrata</i> Extract on the Solubility, Permeability, and Absorption of the Individual Boswellic Acid Constituents Present. Journal of Natural Products, 2012, 75, 1675-1682.	3.0	30
95	Radionuclides in drug development. Drug Discovery Today, 2015, 20, 198-208.	6.4	29
96	Development and characterization of novel highly-loaded itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 175-185.	4.3	28
97	Transport of a fluorescent cAMP analog in teleost proximal tubules. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R2382-R2389.	1.8	27
98	Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases. Pharmaceutical Research, 2015, 32, 2060-2071.	3.5	27
99	Fluorescein-methotrexate transport in rat choroid plexus analyzed using confocal microscopy. American Journal of Physiology - Renal Physiology, 2004, 287, F562-F569.	2.7	26
100	Biological effects of acrylamide after daily ingestion of various foods in comparison to water: A study in rats. Molecular Nutrition and Food Research, 2011, 55, 387-399.	3.3	26
101	Localization Microscopy (SPDM) Reveals Clustered Formations of P-Glycoprotein in a Human Blood-Brain Barrier Model. PLoS ONE, 2012, 7, e44776.	2.5	26
102	Characterization of efflux transport proteins of the human choroid plexus papilloma cell line HIBCPP, a functional in vitro model of the blood-cerebrospinal fluid barrier. Pharmaceutical Research, 2015, 32, 2973-2982.	3.5	26
103	Characterization of immortalized choroid plexus epithelial cell lines for studies of transport processes across the blood-cerebrospinal fluid barrier. Cerebrospinal Fluid Research, 2010, 7, 11.	0.5	25
104	Matrix liposomes: A solid liposomal formulation for oral administration. European Journal of Lipid Science and Technology, 2014, 116, 1145-1154.	1.5	25
105	Cytotoxicity and inhibition of P-glycoprotein by selected medicinal plants from Thailand. Journal of Ethnopharmacology, 2014, 155, 633-641.	4.1	25
106	Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?. Pharmaceutical Research, 2022, 39, 1415-1455.	3.5	24
107	Regional absorption of fexofenadine in rat intestine. European Journal of Pharmaceutical Sciences, 2010, 41, 670-674.	4.0	23
108	Blood-brain barrier models: Rationale for selection. Advanced Drug Delivery Reviews, 2021, 176, 113859.	13.7	23

#	Article	IF	Citations
109	A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2). European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 605-613.	4.3	22
110	Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-Methyl-D-aspartate receptor antagonists—II. Pharmacological characterization in vivo. Neuropharmacology, 1996, 35, 655-669.	4.1	21
111	In vitro Cytotoxicity and P-Glycoprotein Modulating Effects of Geranylated Furocoumarins from Tetradium daniellii. Planta Medica, 2007, 73, 1475-1478.	1.3	21
112	Development of a fluorescence-based assay for drug interactions with human Multidrug Resistance Related Protein (MRP2; ABCC2) in MDCKII-MRP2 membrane vesicles. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 284-290.	4.3	21
113	In vitro and in vivo evaluations of the performance of an indirubin derivative, formulated in four different self-emulsifying drug delivery systems. Journal of Pharmacy and Pharmacology, 2014, 66, 1567-1575.	2.4	20
114	A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. Journal of Medicinal Chemistry, 2017, 60, 6897-6910.	6.4	20
115	Comparative Assessment of Complex Stabilities of Radiocopper Chelating Agents by a Combination of Complex Challenge and in vivo Experiments. ChemMedChem, 2015, 10, 1200-1208.	3.2	18
116	Electrospray Synthesis of Poly(lactide-co-glycolide) Nanoparticles Encapsulating Peptides to Enhance Proliferation of Antigen-Specific CD8+ T Cells. Journal of Pharmaceutical Sciences, 2017, 106, 3316-3327.	3.3	18
117	The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers — An in vitro and in vivo comparison. European Journal of Pharmaceutical Sciences, 2017, 108, 13-22.	4.0	18
118	Crossing the blood-brain barrier: A review on drug delivery strategies using colloidal carrier systems. Neurochemistry International, 2021, 147, 105017.	3.8	17
119	Rapid assessment of p-glycoprotein–drug interactions at the blood–brain barrier. Analytical Biochemistry, 2006, 358, 51-58.	2.4	16
120	Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy. Pharmaceuticals, 2020, 13, 173.	3.8	16
121	Overcoming the Mucosal Barrier: Tetraether Lipidâ€Stabilized Liposomal Nanocarriers Decorated with Cellâ€Penetrating Peptides Enable Oral Delivery of Vancomycin. Advanced Therapeutics, 2021, 4, 2000247.	3.2	16
122	Development and lyophilization of itraconazole loaded poly(butylcyanoacrylate) nanospheres as a drug delivery system. European Journal of Pharmaceutical Sciences, 2015, 78, 121-131.	4.0	15
123	Enterohepatic circulation of scymnol sulfate in an elasmobranch, the little skate (<i>Raja) Tj ETQq1 1 0.784314</i>	rgBT.∤Ove	rlock 10 Tf 50
124	Drug Interactions with Natural Products at the Blood Brain Barrier. Current Drug Metabolism, 2008, 9, 1019-1026.	1.2	14
125	Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay. International Journal of Pharmaceutics, 2012, 422, 52-58.	5. 2	14
126	Zebrafish (<i>Danio rerio</i>) larva as an in vivo vertebrate model to study renal function. American Journal of Physiology - Renal Physiology, 2022, 322, F280-F294.	2.7	14

#	Article	IF	CITATIONS
127	Altered protein expression of membrane transporters in isolated cerebral microvessels and brain cortex of a rat Alzheimer's disease model. Neurobiology of Disease, 2022, 169, 105741.	4.4	14
128	Fluorescein-methotrexate transport in dogfish shark (Squalus acanthias) choroid plexus. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R464-R472.	1.8	13
129	Fluo AMP is transported by multidrug resistanceâ€associated protein isoform 4 in rat choroid plexus. Journal of Neurochemistry, 2010, 115, 200-208.	3.9	13
130	Oral bioavailability of ketoprofen in suspension and solution formulations in rats: the influence of poloxamer 188. Journal of Pharmacy and Pharmacology, 2012, 64, 1631-1637.	2.4	13
131	Lack of biliary lipid excretion in the little skate, Raja erinacea, indicates the absence of functional Mdr2, Abcg5, and Abcg8 transporters. American Journal of Physiology - Renal Physiology, 2004, 286, G762-G768.	3.4	12
132	Physicochemical characterization and in vitro permeation of an indirubin derivative. European Journal of Pharmaceutical Sciences, 2013, 50, 467-475.	4.0	12
133	Side-by-Side Comparison of Five Chelators for 89Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability. Cancers, 2021, 13, 6349.	3.7	12
134	HIV proteinase inhibitors containing 2-aminobenzylstatine as a novel scissile bond replacement: biochemical and pharmacological characterization. Antiviral Research, 1994, 25, 215-233.	4.1	11
135	Texas Red transport across rat and dogfish shark (<i>Squalus acanthias</i>) choroid plexus. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R1311-R1319.	1.8	11
136	Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y1)- and GRP-Receptorsâ€"An Improvement for Breast Cancer Imaging?. Pharmaceuticals, 2018, 11, 65.	3.8	11
137	Aryl hydrocarbon receptor ligands increase ABC transporter activity and protein expression in killifish (<i>Fundulus heteroclitus</i>) renal proximal tubules. Biological Chemistry, 2019, 400, 1335-1345.	2.5	11
138	Retention of structural and functional polarity in cultured skate hepatocytes undergoing in vitro morphogenesis. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2006, 144, 167-179.	1.6	10
139	Inhibition of P-glycoprotein by two artemisinin derivatives. Natural Products and Bioprospecting, 2012, 2, 59-64.	4.3	10
140	NOD-scid IL2R \hat{I}^3 null mice engrafted with human peripheral blood mononuclear cells as a model to test therapeutics targeting human signaling pathways. Journal of Translational Medicine, 2013, 11, 4.	4.4	10
141	Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2771-2775.	2.2	10
142	Zinc chloride rapidly stimulates efflux transporters in renal proximal tubules of killifish (Fundulus) Tj ETQq0 0 0 r	gBT Over	ock 10 Tf 50
143	Dual asymmetric centrifugation as a novel method to prepare highly concentrated dispersions of PEG-b-PCL polymersomes as drug carriers. International Journal of Pharmaceutics, 2020, 579, 119087.	5.2	10
144	Extension of the Mechanistic Tissue Distribution Model of Rodgers and Rowland by Systematic Incorporation of Lysosomal Trapping: Impact on Unbound Partition Coefficient and Volume of Distribution Predictions in the Rat. Drug Metabolism and Disposition, 2021, 49, 53-61.	3.3	10

#	Article	IF	CITATIONS
145	Development and validation of a LC–MS/MS method for assessment of an anti-inflammatory indolinone derivative by in vitro blood–brain barrier models. Journal of Pharmaceutical and Biomedical Analysis, 2014, 98, 235-246.	2.8	9
146	Impact of Zn ²⁺ on ABC Transporter Function in Intact Isolated Rat Brain Microvessels, Human Brain Capillary Endothelial Cells, and in Rat in Vivo. Molecular Pharmaceutics, 2019, 16, 305-317.	4.6	9
147	Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. Pharmaceuticals, 2019, 12, 7.	3.8	9
148	Lipid Profiles of Five Essential Phospholipid Preparations for the Treatment of Nonalcoholic Fatty Liver Disease: A Comparative Study. Lipids, 2020, 55, 271-278.	1.7	9
149	Re-evaluation of the hCMEC/D3 based in vitro BBB model for ABC transporter studies. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 173, 12-21.	4.3	9
150	Drug Delivery Strategies to Overcome the Blood–Brain Barrier (BBB). Handbook of Experimental Pharmacology, 2020, , 151-183.	1.8	8
151	Alkamides from Echinacea angustifolia Interact with P-Glycoprotein of Primary Brain Capillary Endothelial Cells Isolated from Porcine Brain Blood Vessels. Planta Medica, 2013, 79, 214-218.	1.3	7
152	Shuttleâ€"Cargo Fusion Molecules of Transport Peptides and the hD _{2/3} Receptor Antagonist Fallypride: A Feasible Approach To Preserve Ligandâ€"Receptor Binding?. Journal of Medicinal Chemistry, 2014, 57, 4368-4381.	6.4	7
153	Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin αvβ3 and the MC1 Receptorâ€"Suitable for the Specific Visualization of Melanomas?. Pharmaceuticals, 2021, 14, 547.	3.8	7
154	Trends in liposomal nanocarrier strategies for the oral delivery of biologics. Nanomedicine, 2021, 16, 1813-1832.	3.3	7
155	Potential and Limits of Kidney Cells for Evaluation of Renal Excretion. Pharmaceuticals, 2021, 14, 908.	3.8	6
156	InÂVitro and In Situ Characterization of Triterpene Glycosides From Cimicifuga racemosa Extract. Journal of Pharmaceutical Sciences, 2017, 106, 3642-3650.	3.3	5
157	Overcoming MDR at the blood–brain barrier. International Congress Series, 2005, 1277, 131-143.	0.2	4
158	The Blood–Brain Barrier: An Introduction to Its Structure and Function. Topics in Medicinal Chemistry, 2013, , 1-20.	0.8	4
159	Synthesis, in vitro and in vivo evaluation of 18 F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors. Nuclear Medicine and Biology, 2018, 57, 1-11.	0.6	3
160	The influence of liquid intake on the performance of an amorphous solid dispersion in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 296-298.	4.3	3
161	Drug Delivery Across the Blood-Brain Barrier. Current Nanoscience, 2005, 1, 203-209.	1.2	3
162	Synthesis and Characterization of Biodegradable Poly(butyl cyanoacrylate) for Drug Delivery Applications. Polymers, 2022, 14, 998.	4.5	3

#	Article	IF	CITATIONS
163	Vergleichende Untersuchungen zur TeilchengrĶğenanalyse. Chemie-Ingenieur-Technik, 2000, 72, 273-276.	0.8	2
164	Physicochemical and biopharmaceutical characterization of novel Matrix-Liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 158-167.	4.3	2
165	In Vitro Models to Study Blood-Brain Barrier Function. , 2008, , 397-417.		2
166	Intestinal Absorption of Sugar-coupled Somatostatin Analogs. Journal of Pharmaceutical Sciences, 1996, 85, 1211-1214.	3.3	1
167	A simple method to quickly and simultaneously purify and enrich intact rat brain microcapillaries and endothelial and glial cells for ex vivo studies and cell culture. Brain Research, 2013, 1519, 9-18.	2.2	1
168	The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl-Lysophosphatidylethanolamide (UDCA-LPE) Disintegrates the Lipid Backbone of Raft Plasma Membrane Domains by the Removal of the Membrane Phospholipase A2. International Journal of Molecular Sciences, 2019, 20, 5631.	4.1	1
169	<p>Sugar Codes Conjugated Alginate: An Innovative Platform to Make a Strategic Breakthrough in Simultaneous Prophylaxis of GERD and Helicobacter pylori Infection</p> . Drug Design, Development and Therapy, 2020, Volume 14, 2405-2412.	4.3	1
170	David S. Miller: Scientist, Mentor, Friendâ€"a tribute and thank you. Fluids and Barriers of the CNS, 2020, 17, 56.	5.0	0
171	Drug transport across the blood–brain barrier – a molecular and functional perspective. , 2002, , 327-336.		0